Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352102 | 0.94 | EPHX1 (0.54) | EPHX1HTTALDH1A1TLR7GAA | |
| SCHEMBL5346616 | 0.93 | FAAH (0.50) | EPHX1HTTALDH1A1GAALMNA | |
| SCHEMBL1952080 | 0.89 | GAA (0.52) | HTTTLR7GAALMNATP53 | |
| SCHEMBL1950119 | 0.84 | GAA (0.47) | HTTTLR7GAALMNATP53 | |
| SCHEMBL5362901 | 0.84 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL5351916 | 0.83 | EPHX1 (0.45) | EPHX1HTTTLR7GAALMNA | |
| SCHEMBL5362469 | 0.83 | EPHX1 (0.46) | EPHX1HTTALDH1A1TLR7GAA | |
| SCHEMBL4551314 | 0.82 | TLR7 (0.54) | HTTTLR7GAALMNATP53 | |
| SCHEMBL5355736 | 0.81 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL4165503 | 0.81 | TLR7 (0.49) | HTTTLR7GAALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157453-B2 | Urea substituted imidazoquinolines | 3M INNOVATION PROPERTIES COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050131009-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-16 | — | — | US | disclosed |
| US-6897221-B2 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-6784188-B2 | ADMINISTERING TO A MAMMAL 1H-IMIDAZO(4,5-C)QUINOLINE RING CONTAINING COMPOUND FOR THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLSATIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040167154-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-26 | — | — | US | disclosed |
| US-20040019048-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-6573273-B1 | Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167154-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | EPHX1 1608/4885HTT 2375/4885ALDH1A1 1336/4885 |
| US-20040019048-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | EPHX1 1608/4885HTT 2375/4885ALDH1A1 1336/4885 |
| US-20050131009-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | EPHX1 1608/4885HTT 2375/4885ALDH1A1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.